Crossmark

Comparative safety of nivolumab plus ipilimumab versus nivolumab plus relatlimab in advanced melanoma: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS)

Crossref DOI link: https://doi.org/10.1186/s12885-025-14546-6

Published Online: 2025-07-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Shanshan

Song, Zhihui

Wang, Dong

Wang, Ente

Wang, Jiawei
License Information

Text and Data Mining valid from 2025-07-19

Version of Record valid from 2025-07-19
More Information

Article History

Received: 11 April 2025

Accepted: 19 June 2025

First Online: 19 July 2025

Declarations

:

: Not applicable. Ethical approval was not required for this study because we used the FAERS database, which is a free open-access database.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below